STOCK TITAN

Corcept (CORT) files Form 144 for 2,326-share sale via Fidelity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 for Corcept Therapeutics (CORT) shows a proposed sale of 2,326 common shares acquired by stock option exercise on 08/22/2025, with cash payment the same day. The sale is through Fidelity Brokerage Services LLC on NASDAQ and the reported aggregate market value is $165,774.02. The filing also lists a prior sale on 06/16/2025 of 3,185 shares generating $225,402.45. The issuer’s outstanding shares are reported as 105,371,729. The filer certifies no undisclosed material adverse information is known.

Positive

  • Disclosure compliance: The Form 144 provides required public notice of the intended sale, increasing transparency
  • Transaction details provided: Acquisition method (stock option exercise), payment (cash), broker (Fidelity) and aggregate value are all stated

Negative

  • Insider sales reported: A prior sale of 3,185 shares on 06/16/2025 and a proposed sale of 2,326 shares may be viewed unfavorably by some investors

Insights

TL;DR: Routine insider notice of planned sale following option exercise; size is immaterial relative to total shares.

The Form 144 documents a proposed sale of 2,326 shares resulting from a same-day option exercise and cash payment, listed with Fidelity and intended for sale on NASDAQ. The reported aggregate value of $165,774.02 and the prior 3,185-share sale (gross proceeds $225,402.45) are small versus 105.4 million shares outstanding, indicating limited direct impact on share supply or valuation. This filing fulfills Rule 144 disclosure requirements and provides transparency on insider liquidity events.

TL;DR: Disclosure is compliant and routine; no governance red flags apparent from the filing alone.

The notice includes required representations about the absence of undisclosed material adverse information and documents the acquisition method (stock option exercise) and payment in cash. The presence of a prior sale in June is disclosed. There is no information in the filing suggesting unusual trading plans, related-party transfers, or material governance concerns; it appears to be a standard insider liquidity event reported under Rule 144.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What shares does the Form 144 for CORT report for sale?

2,326 common shares acquired by stock option exercise on 08/22/2025, to be sold on NASDAQ through Fidelity Brokerage.

What is the aggregate market value reported for the proposed sale?

$165,774.02 is the aggregate market value reported for the 2,326 shares.

Were there any recent sales by the same person in the past three months?

Yes. A sale of 3,185 shares on 06/16/2025 with gross proceeds of $225,402.45 is disclosed.

How were the 2,326 shares acquired?

They were acquired by stock option exercise from the issuer on 08/22/2025 with payment in cash.

How many shares outstanding does the filing report for the issuer?

The filing reports 105,371,729 shares outstanding for the issuer.
Corcept Therapeutics Inc

NASDAQ:CORT

CORT Rankings

CORT Latest News

CORT Latest SEC Filings

CORT Stock Data

8.69B
92.95M
11.55%
76.02%
10.33%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY